Winter Rheumatology Symposium

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration (payment)
6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
7. Receipt of royalties
8. Speakers' bureau
9. Other

The planning committee and faculty reported the following disclosures.

2019 Winter Rheumatology Symposium Planning Committee Disclosures

• Joel Block, MD – Gilead¹, Novartis², Pfizer, Inc.², Janssen², GlaxoSmithKline⁵, Medivir⁵, Daiichi Sankyo, Inc.⁷, Omeros, Inc.⁷
• Maria Dall’Era, MD – Biogen⁵, Genentech⁵, Kezar⁵, AbbVie⁵
• Michael E. Weinblatt, MD – Canfite¹, Lycera^1,5, Vorso¹, Amgen^2,5, Crescendo^2,5, Bristol-myers Squibb^2,5, Sanofi², Abbvie⁵, Ablynx⁵, Corrona⁵, GSK⁵, Gilead⁵, Lilly⁵, Merch⁵, Momenta⁵, Novartis⁵, Pfizer⁵, Roche⁵, Samsung⁵, Set Point⁵, UCB⁵, Vertex⁵

2019 Winter Rheumatology Faculty Disclosures

• Joel A. Block, MD – Gilead¹, Novartis², Pfizer, Inc.², Janssen², GlaxoSmithKline⁵, Medivir⁵
• Vivian P. Bykerk, MD – Brainstorm¹, Amgen Inc.^2,5, BMS^2,5, Pfizer, Inc.⁵, Regeneron⁵
• Lisa Christopher-Stine, MD, MPH - Velia_bio⁵, Optioncare⁵, Mallinckrodt⁵, Inova Diagnostics⁷, Corbus Pharmaceuticals⁹
• Jean Connors, MD - Bristol-Meyers Squibb⁵
• Maria Dall'Era, MD – AstraZeneca⁵, Genentech, Inc.⁵
• Jon T. Giles, MD, MPH - Genentech, Inc.⁵
• Judith A. James, MD, PhD - No relevant financial relationships to disclose
• Dinesh Khanna, MD, MS - CiVi BioPharma, Inc¹, BAYER², HORIZON², Pfizer, Inc. ², BMS², CiVi BioPharma, Inc³, Actelion⁵, Sanofi⁵, Cytori Therapeutics⁵, Corbus⁵, Boehringer Ingelheim⁵, GSK⁵, Galapagos⁵, Genentech/ Roche⁵, CSL Behring⁵, Bayer⁵
• Joel Kremer, MD – Corrona, LLC¹, Abbvie², Lilly², Genentech², Novartis², Pfizer²
• Peter McBride - No relevant financial relationships to disclose
• W. Joseph McCune, MD - No relevant financial relationships to disclose
• David Pisetsky, MD, PhD - DSMB Celgene⁵, Lilly⁵, DILI-SIM⁵, Celltrion⁵
• Christopher T. Ritchlin, MD, MPH - AbbVie Inc.^1,5, Amgen Inc. ^1,5, UCB, Inc. ^1,5, Novartis⁵, Lilly⁵, Janssen⁵, Pfizer, Inc. ⁵
• Ann Rosenthal, M.D. - No relevant financial relationships to disclose
• Douglas J. Veale, MD, FRCPI - AbbVie Inc.², Pfizer, Inc.^2,5,8, UCB, Inc.⁸, Roche⁸, Janssen⁹
• Michael Weinblatt, MD – Lycera^1,5, Scipher^1,5, Canfite¹, Amgen Inc. ^2,5, Bristol-Myers Squibb^2,5, Crescendo Bioscience^2,5, Sanofi/Regeneron², Ablynx⁵, Corrona, LLC⁵, GlaxoSmithKline⁵, Gilead⁵, Lilly; Merck & Co. ⁵, Novartis, Pfizer, Inc. ⁵ , Roche⁵, Samsung⁵, Set Point⁵, UCB, Inc⁵
• David Wofsy, MD – GlaxoSmithKline⁸, Novartis⁸